New biomarkers found for diabetic kidney disease
Biomarkers found through urinary and exosome proteome profiling have potential for diagnosis and disease monitoring.
List view / Grid view
Articles
Not all neoantigens are created equal
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
The potential of CD24 in cancer immunotherapy
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
Drug Target Review Proteomics eBook 2023
22 December 2023 | By
Download now! Drug Target Review breaks down the potential of stem cells for personalised regenerative medicine, offering practical insights into their role in healthcare.
Women in STEM with Dr Catherine Sheehan
In this special December edition of Women in STEM, we are privileged to feature Dr Catherine Sheehan, a distinguished figure whose journey in the field of STEM has been marked by passion, resilience, and impactful contributions. We explore her experiences, challenges faced, and the transformative impact of her work in…
Drug Target Review Immuno-oncology eBook 2023
22 December 2023 | By
Download this eBook for FREE. Explore cutting-edge immuno-oncology insights through exclusive interviews and studies by leading experts in the field.
Framework for understanding cell organisation and variation
From a database of more than 200,000 high-resolution, three-dimensional images of human induced pluripotent stem cells, researchers have devised a model to quantify cell shape and internal organisation. Susanne Rafelski, Deputy Director of the Allen Institute for Cell Science, revealed details of their study to Drug Target Review.
Drug Target Review – Issue 4 2023
21 December 2023 | By
A new Drug Target Review issue is now ready to download! This issue features articles on CRISPR, personalised medicine and screening.
The future of mRNA biology and AI convergence
In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly…
The first multi-chamber heart organoids developed
The first multi-chamber cardioids derived from hiPSCs have enabled scientists to investigate heart development and defects.
Navigating the neuroscientific landscape with Dr Judy Illes
In a world grappling with the growing spectre of eco-anxiety and the pressing challenges posed by climate change, Dr Judy Illes, a distinguished figure in the field of neuroscience, sheds light on the role neuroscientists play in contributing to the discourse on environmental issues and their profound impact on individual…
AI system develops features of complex brains
An AI system could be used to observe how physical constraints shape brains and impact people with cognitive difficulties.
New understanding of the TMEJ pathway in cancer
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
The first major set of genetic associations found in long COVID
PrecisionLife’s Dr Sayoni Das, a computational biologist who leads the research and development of bioinformatics pipelines that generate biological insights from PrecisionLife’s core technology and support drug discovery programmes, details a new study. Using combinatorial analysis, genetic variants associated with long COVID have been identified and, furthermore, it has been…
The future of lymphoma treatment
In the current landscape of drug discovery, lymphoma poses a significant challenge and opportunity. Researchers are fervently exploring novel therapeutic avenues, such as Antibody-Drug Conjugates (ADCs), to address the complexities of lymphoma. ARC-02, a standout candidate, demonstrates enhanced efficacy and tolerability in lymphoma treatment. While eyeing a diverse ADC pipeline,…